nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—Protein Kinase Inhibitors—Vemurafenib—melanoma	0.492	1	CiPCiCtD
Afatinib—ERBB4—melanoma	0.124	0.456	CbGaD
Afatinib—ERBB2—melanoma	0.0915	0.337	CbGaD
Afatinib—EGFR—Docetaxel—melanoma	0.0585	0.467	CbGbCtD
Afatinib—EGFR—melanoma	0.0433	0.159	CbGaD
Afatinib—ABCG2—Vemurafenib—melanoma	0.0282	0.225	CbGbCtD
Afatinib—ABCG2—Dactinomycin—melanoma	0.0187	0.149	CbGbCtD
Afatinib—ABCB1—melanoma	0.0132	0.0484	CbGaD
Afatinib—ABCG2—Docetaxel—melanoma	0.00966	0.0771	CbGbCtD
Afatinib—ABCB1—Dactinomycin—melanoma	0.00675	0.0539	CbGbCtD
Afatinib—ABCB1—Docetaxel—melanoma	0.00348	0.0278	CbGbCtD
Afatinib—Disease progression—Carmustine—melanoma	0.00119	0.0456	CcSEcCtD
Afatinib—Pulmonary toxicity—Carmustine—melanoma	0.00114	0.0438	CcSEcCtD
Afatinib—DYRK1A—hair follicle—melanoma	0.001	0.12	CbGeAlD
Afatinib—IRAK1—hair follicle—melanoma	0.000779	0.0935	CbGeAlD
Afatinib—ERBB2—neck—melanoma	0.000698	0.0838	CbGeAlD
Afatinib—Cheilitis—Dactinomycin—melanoma	0.000653	0.025	CcSEcCtD
Afatinib—Mucosal inflammation—Bleomycin—melanoma	0.000537	0.0206	CcSEcCtD
Afatinib—ERBB2—skin of body—melanoma	0.000452	0.0543	CbGeAlD
Afatinib—Interstitial lung disease—Bleomycin—melanoma	0.00042	0.0161	CcSEcCtD
Afatinib—Interstitial lung disease—Carmustine—melanoma	0.000367	0.0141	CcSEcCtD
Afatinib—Interstitial lung disease—Temozolomide—melanoma	0.000355	0.0136	CcSEcCtD
Afatinib—EGFR—mammalian vulva—melanoma	0.000349	0.0419	CbGeAlD
Afatinib—EPHA6—head—melanoma	0.00034	0.0408	CbGeAlD
Afatinib—Vandetanib—KDR—melanoma	0.000331	0.257	CrCbGaD
Afatinib—PHKG2—head—melanoma	0.000328	0.0394	CbGeAlD
Afatinib—Dry skin—Vemurafenib—melanoma	0.000327	0.0125	CcSEcCtD
Afatinib—IRAK1—mammalian vulva—melanoma	0.000308	0.037	CbGeAlD
Afatinib—Mucosal inflammation—Docetaxel—melanoma	0.000302	0.0115	CcSEcCtD
Afatinib—BLK—lymph node—melanoma	0.000301	0.0362	CbGeAlD
Afatinib—LCK—mammalian vulva—melanoma	0.000301	0.0361	CbGeAlD
Afatinib—ERBB4—head—melanoma	0.000295	0.0354	CbGeAlD
Afatinib—ERBB2—head—melanoma	0.000295	0.0354	CbGeAlD
Afatinib—Cystitis noninfective—Bleomycin—melanoma	0.000291	0.0111	CcSEcCtD
Afatinib—Cystitis—Bleomycin—melanoma	0.000287	0.011	CcSEcCtD
Afatinib—DYRK1A—head—melanoma	0.000284	0.0341	CbGeAlD
Afatinib—Vandetanib—VEGFA—melanoma	0.00028	0.218	CrCbGaD
Afatinib—Weight decreased—Vemurafenib—melanoma	0.000279	0.0107	CcSEcCtD
Afatinib—Infestation NOS—Vemurafenib—melanoma	0.000275	0.0105	CcSEcCtD
Afatinib—Infestation—Vemurafenib—melanoma	0.000275	0.0105	CcSEcCtD
Afatinib—Bladder pain—Bleomycin—melanoma	0.000269	0.0103	CcSEcCtD
Afatinib—Mouth ulceration—Dactinomycin—melanoma	0.000251	0.00961	CcSEcCtD
Afatinib—Connective tissue disorder—Vemurafenib—melanoma	0.000242	0.00928	CcSEcCtD
Afatinib—Sepsis—Dactinomycin—melanoma	0.000241	0.00922	CcSEcCtD
Afatinib—Vandetanib—EGFR—melanoma	0.000237	0.184	CrCbGaD
Afatinib—Interstitial lung disease—Docetaxel—melanoma	0.000236	0.00903	CcSEcCtD
Afatinib—Dry eye—Temozolomide—melanoma	0.000232	0.00888	CcSEcCtD
Afatinib—Eye disorder—Vemurafenib—melanoma	0.000231	0.00883	CcSEcCtD
Afatinib—PHKG2—lymph node—melanoma	0.00023	0.0276	CbGeAlD
Afatinib—Sepsis—Carmustine—melanoma	0.000225	0.00863	CcSEcCtD
Afatinib—Gefitinib—EGFR—melanoma	0.000225	0.175	CrCbGaD
Afatinib—Mediastinal disorder—Vemurafenib—melanoma	0.000222	0.00851	CcSEcCtD
Afatinib—Alopecia—Vemurafenib—melanoma	0.000218	0.00835	CcSEcCtD
Afatinib—ABL1—eye—melanoma	0.000218	0.0261	CbGeAlD
Afatinib—ABL1—retina—melanoma	0.000216	0.0259	CbGeAlD
Afatinib—Malnutrition—Vemurafenib—melanoma	0.000215	0.00822	CcSEcCtD
Afatinib—Dysgeusia—Vemurafenib—melanoma	0.00021	0.00805	CcSEcCtD
Afatinib—Back pain—Vemurafenib—melanoma	0.000208	0.00795	CcSEcCtD
Afatinib—ERBB2—lymph node—melanoma	0.000206	0.0248	CbGeAlD
Afatinib—Rhinorrhoea—Docetaxel—melanoma	0.000206	0.00789	CcSEcCtD
Afatinib—DYRK1A—lymph node—melanoma	0.000199	0.0239	CbGeAlD
Afatinib—ABL1—skin of body—melanoma	0.000189	0.0227	CbGeAlD
Afatinib—Cough—Vemurafenib—melanoma	0.000187	0.00717	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.000182	0.00695	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.000181	0.00695	CcSEcCtD
Afatinib—EGFR—lymph node—melanoma	0.000175	0.021	CbGeAlD
Afatinib—Infection—Vemurafenib—melanoma	0.000174	0.00667	CcSEcCtD
Afatinib—ABL1—mammalian vulva—melanoma	0.000173	0.0207	CbGeAlD
Afatinib—Nervous system disorder—Vemurafenib—melanoma	0.000172	0.00658	CcSEcCtD
Afatinib—Hypokalaemia—Carmustine—melanoma	0.000172	0.00657	CcSEcCtD
Afatinib—Skin disorder—Vemurafenib—melanoma	0.00017	0.00652	CcSEcCtD
Afatinib—Dehydration—Temozolomide—melanoma	0.000169	0.00649	CcSEcCtD
Afatinib—Weight decreased—Bleomycin—melanoma	0.000169	0.00647	CcSEcCtD
Afatinib—Pneumonia—Bleomycin—melanoma	0.000167	0.00641	CcSEcCtD
Afatinib—Dry skin—Temozolomide—melanoma	0.000167	0.0064	CcSEcCtD
Afatinib—Hypokalaemia—Temozolomide—melanoma	0.000166	0.00635	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Temozolomide—melanoma	0.000164	0.00628	CcSEcCtD
Afatinib—Stomatitis—Bleomycin—melanoma	0.000162	0.00621	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Temozolomide—melanoma	0.000161	0.00615	CcSEcCtD
Afatinib—Pneumonia—Dactinomycin—melanoma	0.000156	0.00598	CcSEcCtD
Afatinib—IRAK1—lymph node—melanoma	0.000154	0.0185	CbGeAlD
Afatinib—Decreased appetite—Vemurafenib—melanoma	0.000152	0.00583	CcSEcCtD
Afatinib—Stomatitis—Dactinomycin—melanoma	0.000151	0.00579	CcSEcCtD
Afatinib—Gastrointestinal disorder—Vemurafenib—melanoma	0.000151	0.00579	CcSEcCtD
Afatinib—Fatigue—Vemurafenib—melanoma	0.000151	0.00578	CcSEcCtD
Afatinib—LCK—lymph node—melanoma	0.000151	0.0181	CbGeAlD
Afatinib—Constipation—Vemurafenib—melanoma	0.00015	0.00574	CcSEcCtD
Afatinib—Upper respiratory tract infection—Temozolomide—melanoma	0.000146	0.0056	CcSEcCtD
Afatinib—Pneumonia—Carmustine—melanoma	0.000146	0.0056	CcSEcCtD
Afatinib—Sepsis—Docetaxel—melanoma	0.000145	0.00555	CcSEcCtD
Afatinib—Renal failure—Carmustine—melanoma	0.000143	0.00547	CcSEcCtD
Afatinib—Weight decreased—Temozolomide—melanoma	0.000142	0.00546	CcSEcCtD
Afatinib—Stomatitis—Carmustine—melanoma	0.000142	0.00542	CcSEcCtD
Afatinib—Urinary tract infection—Carmustine—melanoma	0.000141	0.00541	CcSEcCtD
Afatinib—Pneumonia—Temozolomide—melanoma	0.000141	0.00541	CcSEcCtD
Afatinib—Infestation—Temozolomide—melanoma	0.00014	0.00538	CcSEcCtD
Afatinib—Infestation NOS—Temozolomide—melanoma	0.00014	0.00538	CcSEcCtD
Afatinib—Body temperature increased—Vemurafenib—melanoma	0.000139	0.0053	CcSEcCtD
Afatinib—Stomatitis—Temozolomide—melanoma	0.000137	0.00524	CcSEcCtD
Afatinib—Urinary tract infection—Temozolomide—melanoma	0.000136	0.00523	CcSEcCtD
Afatinib—Hepatobiliary disease—Temozolomide—melanoma	0.000133	0.00509	CcSEcCtD
Afatinib—Alopecia—Bleomycin—melanoma	0.000132	0.00506	CcSEcCtD
Afatinib—Connective tissue disorder—Carmustine—melanoma	0.000128	0.00491	CcSEcCtD
Afatinib—Renal impairment—Docetaxel—melanoma	0.000127	0.00488	CcSEcCtD
Afatinib—ABCB1—blood vessel—melanoma	0.000127	0.0153	CbGeAlD
Afatinib—Asthenia—Vemurafenib—melanoma	0.000126	0.00481	CcSEcCtD
Afatinib—Urinary tract disorder—Temozolomide—melanoma	0.000124	0.00477	CcSEcCtD
Afatinib—Pruritus—Vemurafenib—melanoma	0.000124	0.00475	CcSEcCtD
Afatinib—Connective tissue disorder—Temozolomide—melanoma	0.000124	0.00474	CcSEcCtD
Afatinib—Urethral disorder—Temozolomide—melanoma	0.000124	0.00473	CcSEcCtD
Afatinib—ABL1—head—melanoma	0.000124	0.0148	CbGeAlD
Afatinib—Alopecia—Dactinomycin—melanoma	0.000123	0.00472	CcSEcCtD
Afatinib—Eye disorder—Carmustine—melanoma	0.000122	0.00467	CcSEcCtD
Afatinib—Diarrhoea—Vemurafenib—melanoma	0.00012	0.00459	CcSEcCtD
Afatinib—Eye disorder—Temozolomide—melanoma	0.000118	0.00451	CcSEcCtD
Afatinib—Dizziness—Vemurafenib—melanoma	0.000116	0.00444	CcSEcCtD
Afatinib—Alopecia—Carmustine—melanoma	0.000115	0.00441	CcSEcCtD
Afatinib—Mental disorder—Carmustine—melanoma	0.000114	0.00438	CcSEcCtD
Afatinib—Mediastinal disorder—Temozolomide—melanoma	0.000114	0.00435	CcSEcCtD
Afatinib—Malnutrition—Carmustine—melanoma	0.000114	0.00435	CcSEcCtD
Afatinib—Cough—Bleomycin—melanoma	0.000114	0.00435	CcSEcCtD
Afatinib—Dehydration—Docetaxel—melanoma	0.000113	0.00431	CcSEcCtD
Afatinib—Vomiting—Vemurafenib—melanoma	0.000111	0.00427	CcSEcCtD
Afatinib—Alopecia—Temozolomide—melanoma	0.000111	0.00427	CcSEcCtD
Afatinib—Dry skin—Docetaxel—melanoma	0.000111	0.00425	CcSEcCtD
Afatinib—Rash—Vemurafenib—melanoma	0.00011	0.00423	CcSEcCtD
Afatinib—Mental disorder—Temozolomide—melanoma	0.00011	0.00423	CcSEcCtD
Afatinib—Dermatitis—Vemurafenib—melanoma	0.00011	0.00423	CcSEcCtD
Afatinib—Back pain—Carmustine—melanoma	0.00011	0.00421	CcSEcCtD
Afatinib—Headache—Vemurafenib—melanoma	0.00011	0.0042	CcSEcCtD
Afatinib—Malnutrition—Temozolomide—melanoma	0.00011	0.0042	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000109	0.00418	CcSEcCtD
Afatinib—ABCG2—mammalian vulva—melanoma	0.000109	0.0131	CbGeAlD
Afatinib—Nasopharyngitis—Docetaxel—melanoma	0.000108	0.00415	CcSEcCtD
Afatinib—Dysgeusia—Temozolomide—melanoma	0.000107	0.00411	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Docetaxel—melanoma	0.000107	0.00409	CcSEcCtD
Afatinib—Back pain—Temozolomide—melanoma	0.000106	0.00406	CcSEcCtD
Afatinib—Infection—Bleomycin—melanoma	0.000105	0.00404	CcSEcCtD
Afatinib—Nausea—Vemurafenib—melanoma	0.000104	0.00399	CcSEcCtD
Afatinib—Infection—Dactinomycin—melanoma	9.84e-05	0.00377	CcSEcCtD
Afatinib—Cough—Temozolomide—melanoma	9.58e-05	0.00367	CcSEcCtD
Afatinib—Weight decreased—Docetaxel—melanoma	9.48e-05	0.00363	CcSEcCtD
Afatinib—Dyspnoea—Bleomycin—melanoma	9.47e-05	0.00362	CcSEcCtD
Afatinib—Pneumonia—Docetaxel—melanoma	9.39e-05	0.0036	CcSEcCtD
Afatinib—Infestation NOS—Docetaxel—melanoma	9.34e-05	0.00358	CcSEcCtD
Afatinib—Infestation—Docetaxel—melanoma	9.34e-05	0.00358	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	9.28e-05	0.00355	CcSEcCtD
Afatinib—Decreased appetite—Bleomycin—melanoma	9.23e-05	0.00353	CcSEcCtD
Afatinib—Infection—Carmustine—melanoma	9.21e-05	0.00353	CcSEcCtD
Afatinib—Renal failure—Docetaxel—melanoma	9.18e-05	0.00351	CcSEcCtD
Afatinib—Stomatitis—Docetaxel—melanoma	9.1e-05	0.00349	CcSEcCtD
Afatinib—Conjunctivitis—Docetaxel—melanoma	9.08e-05	0.00348	CcSEcCtD
Afatinib—Infection—Temozolomide—melanoma	8.9e-05	0.00341	CcSEcCtD
Afatinib—Hepatobiliary disease—Docetaxel—melanoma	8.83e-05	0.00338	CcSEcCtD
Afatinib—Epistaxis—Docetaxel—melanoma	8.81e-05	0.00337	CcSEcCtD
Afatinib—Nervous system disorder—Temozolomide—melanoma	8.78e-05	0.00336	CcSEcCtD
Afatinib—Skin disorder—Temozolomide—melanoma	8.7e-05	0.00333	CcSEcCtD
Afatinib—ABL1—lymph node—melanoma	8.65e-05	0.0104	CbGeAlD
Afatinib—Decreased appetite—Dactinomycin—melanoma	8.61e-05	0.0033	CcSEcCtD
Afatinib—Fatigue—Dactinomycin—melanoma	8.54e-05	0.00327	CcSEcCtD
Afatinib—Body temperature increased—Bleomycin—melanoma	8.39e-05	0.00321	CcSEcCtD
Afatinib—Insomnia—Carmustine—melanoma	8.38e-05	0.00321	CcSEcCtD
Afatinib—Urinary tract disorder—Docetaxel—melanoma	8.28e-05	0.00317	CcSEcCtD
Afatinib—Dyspnoea—Carmustine—melanoma	8.26e-05	0.00316	CcSEcCtD
Afatinib—Connective tissue disorder—Docetaxel—melanoma	8.24e-05	0.00315	CcSEcCtD
Afatinib—Urethral disorder—Docetaxel—melanoma	8.22e-05	0.00315	CcSEcCtD
Afatinib—Insomnia—Temozolomide—melanoma	8.1e-05	0.0031	CcSEcCtD
Afatinib—Decreased appetite—Carmustine—melanoma	8.06e-05	0.00308	CcSEcCtD
Afatinib—Gastrointestinal disorder—Carmustine—melanoma	8e-05	0.00306	CcSEcCtD
Afatinib—Dyspnoea—Temozolomide—melanoma	7.98e-05	0.00306	CcSEcCtD
Afatinib—Constipation—Carmustine—melanoma	7.92e-05	0.00303	CcSEcCtD
Afatinib—Dyspepsia—Temozolomide—melanoma	7.88e-05	0.00302	CcSEcCtD
Afatinib—Eye disorder—Docetaxel—melanoma	7.83e-05	0.003	CcSEcCtD
Afatinib—Body temperature increased—Dactinomycin—melanoma	7.83e-05	0.003	CcSEcCtD
Afatinib—Decreased appetite—Temozolomide—melanoma	7.79e-05	0.00298	CcSEcCtD
Afatinib—Gastrointestinal disorder—Temozolomide—melanoma	7.73e-05	0.00296	CcSEcCtD
Afatinib—Fatigue—Temozolomide—melanoma	7.72e-05	0.00296	CcSEcCtD
Afatinib—Constipation—Temozolomide—melanoma	7.66e-05	0.00293	CcSEcCtD
Afatinib—Asthenia—Bleomycin—melanoma	7.62e-05	0.00292	CcSEcCtD
Afatinib—Mediastinal disorder—Docetaxel—melanoma	7.56e-05	0.00289	CcSEcCtD
Afatinib—Vandetanib—ALB—melanoma	7.54e-05	0.0585	CrCbGaD
Afatinib—Pruritus—Bleomycin—melanoma	7.51e-05	0.00288	CcSEcCtD
Afatinib—Alopecia—Docetaxel—melanoma	7.41e-05	0.00284	CcSEcCtD
Afatinib—Mental disorder—Docetaxel—melanoma	7.34e-05	0.00281	CcSEcCtD
Afatinib—Body temperature increased—Carmustine—melanoma	7.33e-05	0.00281	CcSEcCtD
Afatinib—Malnutrition—Docetaxel—melanoma	7.3e-05	0.00279	CcSEcCtD
Afatinib—Gefitinib—ALB—melanoma	7.16e-05	0.0556	CrCbGaD
Afatinib—Dysgeusia—Docetaxel—melanoma	7.15e-05	0.00274	CcSEcCtD
Afatinib—Asthenia—Dactinomycin—melanoma	7.1e-05	0.00272	CcSEcCtD
Afatinib—Body temperature increased—Temozolomide—melanoma	7.08e-05	0.00271	CcSEcCtD
Afatinib—Back pain—Docetaxel—melanoma	7.06e-05	0.0027	CcSEcCtD
Afatinib—Muscle spasms—Docetaxel—melanoma	7.02e-05	0.00269	CcSEcCtD
Afatinib—Gefitinib—ABCB1—melanoma	6.84e-05	0.0531	CrCbGaD
Afatinib—Diarrhoea—Dactinomycin—melanoma	6.77e-05	0.00259	CcSEcCtD
Afatinib—Vomiting—Bleomycin—melanoma	6.75e-05	0.00258	CcSEcCtD
Afatinib—ABCB1—retina—melanoma	6.71e-05	0.00805	CbGeAlD
Afatinib—Rash—Bleomycin—melanoma	6.69e-05	0.00256	CcSEcCtD
Afatinib—Dermatitis—Bleomycin—melanoma	6.69e-05	0.00256	CcSEcCtD
Afatinib—Asthenia—Carmustine—melanoma	6.65e-05	0.00255	CcSEcCtD
Afatinib—Asthenia—Temozolomide—melanoma	6.43e-05	0.00246	CcSEcCtD
Afatinib—Cough—Docetaxel—melanoma	6.37e-05	0.00244	CcSEcCtD
Afatinib—Diarrhoea—Carmustine—melanoma	6.34e-05	0.00243	CcSEcCtD
Afatinib—Pruritus—Temozolomide—melanoma	6.34e-05	0.00243	CcSEcCtD
Afatinib—Nausea—Bleomycin—melanoma	6.31e-05	0.00241	CcSEcCtD
Afatinib—Vomiting—Dactinomycin—melanoma	6.3e-05	0.00241	CcSEcCtD
Afatinib—Rash—Dactinomycin—melanoma	6.24e-05	0.00239	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	6.17e-05	0.00236	CcSEcCtD
Afatinib—Dizziness—Carmustine—melanoma	6.13e-05	0.00235	CcSEcCtD
Afatinib—Diarrhoea—Temozolomide—melanoma	6.13e-05	0.00235	CcSEcCtD
Afatinib—Dizziness—Temozolomide—melanoma	5.92e-05	0.00227	CcSEcCtD
Afatinib—Infection—Docetaxel—melanoma	5.92e-05	0.00227	CcSEcCtD
Afatinib—Vomiting—Carmustine—melanoma	5.89e-05	0.00226	CcSEcCtD
Afatinib—Nausea—Dactinomycin—melanoma	5.88e-05	0.00225	CcSEcCtD
Afatinib—Rash—Carmustine—melanoma	5.84e-05	0.00224	CcSEcCtD
Afatinib—Nervous system disorder—Docetaxel—melanoma	5.84e-05	0.00224	CcSEcCtD
Afatinib—Dermatitis—Carmustine—melanoma	5.84e-05	0.00224	CcSEcCtD
Afatinib—Headache—Carmustine—melanoma	5.81e-05	0.00222	CcSEcCtD
Afatinib—Skin disorder—Docetaxel—melanoma	5.78e-05	0.00222	CcSEcCtD
Afatinib—Vomiting—Temozolomide—melanoma	5.69e-05	0.00218	CcSEcCtD
Afatinib—Rash—Temozolomide—melanoma	5.65e-05	0.00216	CcSEcCtD
Afatinib—Dermatitis—Temozolomide—melanoma	5.64e-05	0.00216	CcSEcCtD
Afatinib—Headache—Temozolomide—melanoma	5.61e-05	0.00215	CcSEcCtD
Afatinib—Nausea—Carmustine—melanoma	5.5e-05	0.00211	CcSEcCtD
Afatinib—ABCG2—lymph node—melanoma	5.46e-05	0.00655	CbGeAlD
Afatinib—Insomnia—Docetaxel—melanoma	5.39e-05	0.00206	CcSEcCtD
Afatinib—ABCB1—mammalian vulva—melanoma	5.37e-05	0.00645	CbGeAlD
Afatinib—Nausea—Temozolomide—melanoma	5.32e-05	0.00204	CcSEcCtD
Afatinib—Dyspnoea—Docetaxel—melanoma	5.31e-05	0.00203	CcSEcCtD
Afatinib—Dyspepsia—Docetaxel—melanoma	5.24e-05	0.00201	CcSEcCtD
Afatinib—Decreased appetite—Docetaxel—melanoma	5.18e-05	0.00198	CcSEcCtD
Afatinib—Gastrointestinal disorder—Docetaxel—melanoma	5.14e-05	0.00197	CcSEcCtD
Afatinib—Fatigue—Docetaxel—melanoma	5.13e-05	0.00197	CcSEcCtD
Afatinib—Constipation—Docetaxel—melanoma	5.09e-05	0.00195	CcSEcCtD
Afatinib—Body temperature increased—Docetaxel—melanoma	4.71e-05	0.0018	CcSEcCtD
Afatinib—Asthenia—Docetaxel—melanoma	4.27e-05	0.00164	CcSEcCtD
Afatinib—Pruritus—Docetaxel—melanoma	4.21e-05	0.00161	CcSEcCtD
Afatinib—Diarrhoea—Docetaxel—melanoma	4.07e-05	0.00156	CcSEcCtD
Afatinib—Dizziness—Docetaxel—melanoma	3.94e-05	0.00151	CcSEcCtD
Afatinib—ABCB1—head—melanoma	3.84e-05	0.00461	CbGeAlD
Afatinib—Vomiting—Docetaxel—melanoma	3.79e-05	0.00145	CcSEcCtD
Afatinib—Rash—Docetaxel—melanoma	3.76e-05	0.00144	CcSEcCtD
Afatinib—Dermatitis—Docetaxel—melanoma	3.75e-05	0.00144	CcSEcCtD
Afatinib—Headache—Docetaxel—melanoma	3.73e-05	0.00143	CcSEcCtD
Afatinib—Nausea—Docetaxel—melanoma	3.54e-05	0.00135	CcSEcCtD
Afatinib—ABCB1—lymph node—melanoma	2.69e-05	0.00323	CbGeAlD
Afatinib—ERBB2—Signaling Pathways—MYC—melanoma	8.74e-07	1.17e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HIF1A—melanoma	8.72e-07	1.16e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—AKT1—melanoma	8.66e-07	1.16e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MDM2—melanoma	8.64e-07	1.15e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MYC—melanoma	8.61e-07	1.15e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	8.59e-07	1.15e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—FASN—melanoma	8.57e-07	1.14e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CG—melanoma	8.57e-07	1.14e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MAPK1—melanoma	8.55e-07	1.14e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EGFR—melanoma	8.55e-07	1.14e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDKN1B—melanoma	8.54e-07	1.14e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—AKT1—melanoma	8.53e-07	1.14e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—ERBB2—melanoma	8.52e-07	1.14e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HRAS—melanoma	8.49e-07	1.13e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HRAS—melanoma	8.46e-07	1.13e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CXCL8—melanoma	8.46e-07	1.13e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—IL6—melanoma	8.44e-07	1.13e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SLC5A5—melanoma	8.43e-07	1.13e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MAPK1—melanoma	8.42e-07	1.12e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EGFR—melanoma	8.42e-07	1.12e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CB—melanoma	8.4e-07	1.12e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HIF1A—melanoma	8.4e-07	1.12e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CD4—melanoma	8.39e-07	1.12e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL2—melanoma	8.36e-07	1.12e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KDR—melanoma	8.34e-07	1.11e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—AKT1—melanoma	8.33e-07	1.11e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—melanoma	8.33e-07	1.11e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MDM2—melanoma	8.32e-07	1.11e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—PIK3CA—melanoma	8.3e-07	1.11e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PPARG—melanoma	8.28e-07	1.1e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CDKN1B—melanoma	8.26e-07	1.1e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CDKN1B—melanoma	8.23e-07	1.1e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—STAT3—melanoma	8.23e-07	1.1e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—NRAS—melanoma	8.21e-07	1.1e-05	CbGpPWpGaD
Afatinib—LCK—Disease—ERBB2—melanoma	8.21e-07	1.1e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HRAS—melanoma	8.16e-07	1.09e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GNAQ—melanoma	8.15e-07	1.09e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CD44—melanoma	8.15e-07	1.09e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IL6—melanoma	8.13e-07	1.08e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CB—melanoma	8.1e-07	1.08e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CASP3—melanoma	8.09e-07	1.08e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CD4—melanoma	8.08e-07	1.08e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL2—melanoma	8.08e-07	1.08e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KRAS—melanoma	8.08e-07	1.08e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CTNNB1—melanoma	8.07e-07	1.08e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL2—melanoma	8.06e-07	1.07e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KDR—melanoma	8.03e-07	1.07e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FN1—melanoma	8.03e-07	1.07e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—melanoma	8.02e-07	1.07e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KRAS—melanoma	7.96e-07	1.06e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CDKN1B—melanoma	7.89e-07	1.05e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDKN1A—melanoma	7.88e-07	1.05e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCND1—melanoma	7.88e-07	1.05e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PTEN—melanoma	7.87e-07	1.05e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—MAPK3—melanoma	7.86e-07	1.05e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOTCH1—melanoma	7.85e-07	1.05e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—NFKB1—melanoma	7.83e-07	1.04e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP1B1—melanoma	7.81e-07	1.04e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CTNNB1—melanoma	7.8e-07	1.04e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—AKT1—melanoma	7.78e-07	1.04e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CTNNB1—melanoma	7.78e-07	1.04e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FN1—melanoma	7.73e-07	1.03e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CD80—melanoma	7.69e-07	1.03e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CG—melanoma	7.68e-07	1.02e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APC—melanoma	7.68e-07	1.02e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KIT—melanoma	7.68e-07	1.02e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—NRAS—melanoma	7.68e-07	1.02e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HRAS—melanoma	7.68e-07	1.02e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—melanoma	7.65e-07	1.02e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CDKN1A—melanoma	7.62e-07	1.02e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PTEN—melanoma	7.6e-07	1.01e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CDKN1B—melanoma	7.6e-07	1.01e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CDKN1A—melanoma	7.6e-07	1.01e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—EGF—melanoma	7.59e-07	1.01e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PTEN—melanoma	7.58e-07	1.01e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NFKB1—melanoma	7.57e-07	1.01e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOTCH1—melanoma	7.57e-07	1.01e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—NFKB1—melanoma	7.54e-07	1.01e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CD—melanoma	7.54e-07	1.01e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—AKT1—melanoma	7.5e-07	1e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—MAPK1—melanoma	7.48e-07	9.99e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—EGFR—melanoma	7.48e-07	9.98e-06	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—AKT1—melanoma	7.47e-07	9.97e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—CTNNB1—melanoma	7.45e-07	9.94e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ALB—melanoma	7.44e-07	9.93e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PIK3CA—melanoma	7.42e-07	9.9e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CD80—melanoma	7.41e-07	9.89e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KIT—melanoma	7.4e-07	9.88e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APC—melanoma	7.4e-07	9.88e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CG—melanoma	7.4e-07	9.88e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—MAPK3—melanoma	7.36e-07	9.81e-06	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL6—melanoma	7.35e-07	9.81e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGF—melanoma	7.32e-07	9.76e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PIK3CA—melanoma	7.31e-07	9.75e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—CDKN1A—melanoma	7.28e-07	9.71e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—PTEN—melanoma	7.26e-07	9.69e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—BRAF—melanoma	7.22e-07	9.63e-06	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—AKT1—melanoma	7.2e-07	9.61e-06	CbGpPWpGaD
Afatinib—LCK—Disease—CTNNB1—melanoma	7.18e-07	9.58e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—melanoma	7.18e-07	9.58e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—melanoma	7.07e-07	9.44e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—KRAS—melanoma	7.07e-07	9.43e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—STAT3—melanoma	7.03e-07	9.39e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IGF1—melanoma	7.03e-07	9.38e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—NRAS—melanoma	7.02e-07	9.36e-06	CbGpPWpGaD
Afatinib—LCK—Disease—CDKN1A—melanoma	7.01e-07	9.36e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—MAPK1—melanoma	7e-07	9.34e-06	CbGpPWpGaD
Afatinib—LCK—Disease—PTEN—melanoma	7e-07	9.34e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—BRAF—melanoma	6.96e-07	9.28e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—melanoma	6.87e-07	9.17e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HRAS—melanoma	6.87e-07	9.16e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—STAT3—melanoma	6.8e-07	9.08e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAP2K1—melanoma	6.8e-07	9.07e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NRAS—melanoma	6.78e-07	9.05e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—STAT3—melanoma	6.78e-07	9.05e-06	CbGpPWpGaD
Afatinib—IRAK1—Immune System—AKT1—melanoma	6.78e-07	9.05e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IGF1—melanoma	6.78e-07	9.04e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HRAS—melanoma	6.76e-07	9.02e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—NRAS—melanoma	6.76e-07	9.02e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CD—melanoma	6.75e-07	9.01e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK3—melanoma	6.72e-07	8.97e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—KRAS—melanoma	6.61e-07	8.82e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL6—melanoma	6.57e-07	8.77e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CB—melanoma	6.57e-07	8.77e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAP2K1—melanoma	6.55e-07	8.74e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—melanoma	6.51e-07	8.69e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CD—melanoma	6.51e-07	8.68e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK3—melanoma	6.5e-07	8.67e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—STAT3—melanoma	6.49e-07	8.67e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—PIK3CA—melanoma	6.49e-07	8.66e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—NRAS—melanoma	6.48e-07	8.65e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK3—melanoma	6.48e-07	8.64e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL6—melanoma	6.47e-07	8.64e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FGF2—melanoma	6.46e-07	8.63e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK1—melanoma	6.39e-07	8.53e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MYC—melanoma	6.32e-07	8.43e-06	CbGpPWpGaD
Afatinib—LCK—Disease—STAT3—melanoma	6.26e-07	8.35e-06	CbGpPWpGaD
Afatinib—LCK—Disease—NRAS—melanoma	6.24e-07	8.33e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGF2—melanoma	6.23e-07	8.31e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—MAPK3—melanoma	6.2e-07	8.28e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK1—melanoma	6.18e-07	8.25e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EGFR—melanoma	6.18e-07	8.25e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK1—melanoma	6.16e-07	8.22e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—EGFR—melanoma	6.16e-07	8.22e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PIK3CA—melanoma	6.07e-07	8.1e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AKT1—melanoma	6.06e-07	8.09e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MDM2—melanoma	6.05e-07	8.07e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—KRAS—melanoma	6.04e-07	8.06e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—MYC—melanoma	6.03e-07	8.05e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—HRAS—melanoma	6.01e-07	8.02e-06	CbGpPWpGaD
Afatinib—LCK—Disease—MAPK3—melanoma	5.98e-07	7.98e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AKT1—melanoma	5.97e-07	7.97e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ERBB2—melanoma	5.96e-07	7.96e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PRKCA—melanoma	5.92e-07	7.9e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—MAPK1—melanoma	5.9e-07	7.88e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CB—melanoma	5.88e-07	7.85e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ERCC2—melanoma	5.87e-07	7.83e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KRAS—melanoma	5.84e-07	7.79e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MDM2—melanoma	5.83e-07	7.78e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—KRAS—melanoma	5.82e-07	7.77e-06	CbGpPWpGaD
Afatinib—LCK—Disease—MYC—melanoma	5.82e-07	7.76e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6—melanoma	5.75e-07	7.67e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ERBB2—melanoma	5.75e-07	7.67e-06	CbGpPWpGaD
Afatinib—LCK—Disease—MAPK1—melanoma	5.69e-07	7.59e-06	CbGpPWpGaD
Afatinib—LCK—Disease—EGFR—melanoma	5.69e-07	7.59e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTEN—melanoma	5.68e-07	7.58e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CB—melanoma	5.67e-07	7.57e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL8—melanoma	5.66e-07	7.55e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—HRAS—melanoma	5.62e-07	7.5e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—KRAS—melanoma	5.58e-07	7.44e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CA—melanoma	5.55e-07	7.4e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN1B—melanoma	5.52e-07	7.37e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL8—melanoma	5.45e-07	7.27e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CASP3—melanoma	5.41e-07	7.22e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL2—melanoma	5.4e-07	7.21e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6—melanoma	5.38e-07	7.18e-06	CbGpPWpGaD
Afatinib—LCK—Disease—KRAS—melanoma	5.37e-07	7.17e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CA—melanoma	5.36e-07	7.16e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CA—melanoma	5.35e-07	7.14e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN1B—melanoma	5.32e-07	7.1e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—AKT1—melanoma	5.3e-07	7.08e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCND1—melanoma	5.27e-07	7.03e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CTNNB1—melanoma	5.22e-07	6.96e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CASP3—melanoma	5.22e-07	6.96e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL2—melanoma	5.21e-07	6.95e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—melanoma	5.19e-07	6.93e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—HRAS—melanoma	5.13e-07	6.85e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CA—melanoma	5.12e-07	6.84e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—melanoma	5.11e-07	6.83e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN1A—melanoma	5.1e-07	6.8e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTEN—melanoma	5.09e-07	6.79e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCND1—melanoma	5.08e-07	6.78e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NFKB1—melanoma	5.06e-07	6.75e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CTNNB1—melanoma	5.03e-07	6.71e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HRAS—melanoma	4.96e-07	6.62e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AKT1—melanoma	4.96e-07	6.62e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—HRAS—melanoma	4.95e-07	6.6e-06	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CA—melanoma	4.94e-07	6.59e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—melanoma	4.93e-07	6.58e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6—melanoma	4.91e-07	6.56e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN1A—melanoma	4.91e-07	6.55e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTEN—melanoma	4.9e-07	6.54e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NFKB1—melanoma	4.88e-07	6.51e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6—melanoma	4.75e-07	6.34e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—HRAS—melanoma	4.74e-07	6.32e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6—melanoma	4.73e-07	6.32e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CG—melanoma	4.64e-07	6.19e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—melanoma	4.59e-07	6.13e-06	CbGpPWpGaD
Afatinib—LCK—Disease—HRAS—melanoma	4.57e-07	6.1e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STAT3—melanoma	4.55e-07	6.07e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NRAS—melanoma	4.54e-07	6.05e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6—melanoma	4.54e-07	6.05e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—AKT1—melanoma	4.53e-07	6.05e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPARG—melanoma	4.47e-07	5.97e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—melanoma	4.43e-07	5.91e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AKT1—melanoma	4.38e-07	5.85e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STAT3—melanoma	4.38e-07	5.85e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NRAS—melanoma	4.37e-07	5.83e-06	CbGpPWpGaD
Afatinib—LCK—Disease—IL6—melanoma	4.37e-07	5.83e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—AKT1—melanoma	4.37e-07	5.83e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK3—melanoma	4.34e-07	5.8e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MYC—melanoma	4.23e-07	5.64e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK3—melanoma	4.19e-07	5.59e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—AKT1—melanoma	4.18e-07	5.58e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK1—melanoma	4.13e-07	5.52e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CD—melanoma	4.08e-07	5.44e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MYC—melanoma	4.07e-07	5.43e-06	CbGpPWpGaD
Afatinib—LCK—Disease—AKT1—melanoma	4.03e-07	5.38e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ALB—melanoma	4.02e-07	5.37e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CA—melanoma	4.01e-07	5.34e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK1—melanoma	3.98e-07	5.32e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGFR—melanoma	3.98e-07	5.32e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KRAS—melanoma	3.9e-07	5.21e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KRAS—melanoma	3.76e-07	5.02e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CA—melanoma	3.59e-07	4.79e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CB—melanoma	3.55e-07	4.74e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—melanoma	3.52e-07	4.7e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—melanoma	3.47e-07	4.63e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CA—melanoma	3.46e-07	4.61e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—melanoma	3.34e-07	4.46e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HRAS—melanoma	3.32e-07	4.43e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AKT1—melanoma	3.27e-07	4.37e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HRAS—melanoma	3.2e-07	4.27e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6—melanoma	3.18e-07	4.24e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTEN—melanoma	3.07e-07	4.1e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6—melanoma	3.06e-07	4.09e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT1—melanoma	2.93e-07	3.91e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT1—melanoma	2.82e-07	3.77e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CA—melanoma	2.17e-07	2.89e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKT1—melanoma	1.77e-07	2.36e-06	CbGpPWpGaD
